Highlights from eyeforpharmas Forecasting coverage
New challenges and techniques in forecasting
Peter Mansell explores how forecasters are developing new methods and new metrics to enable them to make better guesses
https://www.reutersevents.com/pharma/forecasting/new-challenges-and-techniques-forecasting
Pharma forecasting: To offshore or not to offshore?
Peter Mansell examines the business arguments for centralized versus departmental or regional forecasting
https://www.reutersevents.com/pharma/forecasting/pharma-forecasting-offshore-or-not-offshore
Patent expiration: Innovate or die
Pharma is unprepared for the blockbuster patent expirations due over the next few years. Angelo DePalma argues that innovation is the only strategic solution
https://www.reutersevents.com/pharma/forecasting/patent-expiration-innovate-or-die
Forecasting for generic erosion rates
Carla Peek, head of business modeling and analytics at InPharmation, on how to create forecasts that account for the market impact of generics
https://www.reutersevents.com/pharma/forecasting/forecasting-generic-erosion-rates
Unlocking the hidden value of forecasting
Alec Finney, principal at Rivershill Consultancy, explains how forecasting discrepancies can enable better business decisions
https://www.reutersevents.com/pharma/forecasting/unlocking-hidden-value-forecasting
Leveraging launch experience in pharma's emerging markets
With the right sales planning and forecasting processes, companies can unlock value in the fast-expanding pharmerging universe, argues Stephanie Hall, Uptake Strategies managing director
https://www.reutersevents.com/pharma/sales/leveraging-launch-experience-pharmas-emerging-markets
Forecasting for emerging pharma markets
Carl Schmidt and Sandeep Sugla of MarketsandMarkets on why forecasting for emerging markets requires different methods and different expectations
https://www.reutersevents.com/pharma/forecasting/forecasting-emerging-pharma-markets
Biomarkers and oncology forecasting: How to hit a moving target
Peter Mansell investigates why biomarkers and other molecular diagnostic tools may be the most undervalued area in oncology
https://www.reutersevents.com/pharma/sales/biomarkers-and-oncology-forecasting-how-hit-moving-target
Forecasting for pharmerging markets
Peter Mansell explores why new forecasting models and methods are needed as pharmaceutical companies increasingly turn to emerging markets to offset faltering growth.
https://www.reutersevents.com/pharma/story/forecasting-%E2%80%98pharmerging%E2%80%99-markets
Forecasting for orphan drugs: The data challenge
Gianclaudio Floria, senior manager for business planning and analysis at Amgen, on best practice in forecasting for orphan drug development.
https://www.reutersevents.com/pharma/forecasting/forecasting-orphan-drugs-data-challenge
Forecasting for complex diseases
Peter Mansell reports on how advances in molecular and cell biology are making the forecasters job more complexand more business critical.
https://www.reutersevents.com/pharma/forecasting/forecasting-complex-diseases
For all the latest business analysis and insight for the pharma industry, sign up to eyeforpharmas newsletters.